Cancers & treatments·Regimen libraryAdjuvant

mFOLFIRINOX (adjuvant)

Checked 2026-09-09

Resected pancreatic cancer, fit patients, started within 12 weeks of surgery

One cycle

every 14 days × 12 · about 24 weeks in total

14-day cycle × 12 (6 months) (about 24 weeks)Intravenous Continuous infusion

Components

Drug	Dose	Route	Days	Note
Oxaliplatin Third-generation platinum (DACH-platinum)	85 mg/m²	IV	D1
Irinotecan Topoisomerase I inhibitor (camptothecin prodrug)	150 mg/m²	IV	D1
Leucovorin (folinic acid)	400 mg/m²	IV	D1	2-hour infusion before fluorouracil
Fluorouracil infusion Fluoropyrimidine antimetabolite	2,400 mg/m²	IV	D1, 2 (46 h infusion)	no bolus

Cycles

12 (6 months)

14-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Consider (10-20% FN risk)

Notes

Median OS 54.4 vs 35.0 months against gemcitabine; irinotecan was reduced from 180 to 150 mg/m² after early toxicity.

Used in

Pancreatic ductal adenocarcinoma

Trials

PRODIGE 24 / CCTG PA6

Products

FOLFIRINOX / mFOLFIRINOXOxaliplatinIrinotecan (and liposomal irinotecan)Fluorouracil (5-FU)

Source

PRODIGE 24 / CCTG PA6, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.